* Tg Therapeutics Inc. announces oral data presentation for
tgr-1202 in combination with ibrutinib in patients with relapsed
or refractory cll or mcl at the 58th american society of
hematology annual…
The post BRIEF-TG Therapeutics presents phase 1b data for TGR-1202 in combination with ibrutinib appeared first on NASDAQ.